ATE449776T1 - Pyrroloä2,3-cüpyridinderivate - Google Patents

Pyrroloä2,3-cüpyridinderivate

Info

Publication number
ATE449776T1
ATE449776T1 AT06830343T AT06830343T ATE449776T1 AT E449776 T1 ATE449776 T1 AT E449776T1 AT 06830343 T AT06830343 T AT 06830343T AT 06830343 T AT06830343 T AT 06830343T AT E449776 T1 ATE449776 T1 AT E449776T1
Authority
AT
Austria
Prior art keywords
pyrroloä2
cüpyridine
derivatives
sup
compounds
Prior art date
Application number
AT06830343T
Other languages
English (en)
Inventor
Matthias Nettekoven
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE449776T1 publication Critical patent/ATE449776T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Table Devices Or Equipment (AREA)
  • Peptides Or Proteins (AREA)
AT06830343T 2005-12-15 2006-12-05 Pyrroloä2,3-cüpyridinderivate ATE449776T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112186 2005-12-15
PCT/EP2006/069289 WO2007068620A1 (en) 2005-12-15 2006-12-05 Pyrrolo[2,3-c]pyridine derivatives

Publications (1)

Publication Number Publication Date
ATE449776T1 true ATE449776T1 (de) 2009-12-15

Family

ID=37728403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830343T ATE449776T1 (de) 2005-12-15 2006-12-05 Pyrroloä2,3-cüpyridinderivate

Country Status (13)

Country Link
US (1) US7348323B2 (de)
EP (1) EP1963318B1 (de)
JP (1) JP2009519290A (de)
KR (1) KR20080068127A (de)
CN (1) CN101326187A (de)
AT (1) ATE449776T1 (de)
AU (1) AU2006326135A1 (de)
BR (1) BRPI0619989A2 (de)
CA (1) CA2631694A1 (de)
DE (1) DE602006010738D1 (de)
ES (1) ES2334580T3 (de)
IL (1) IL191751A0 (de)
WO (1) WO2007068620A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2110374A1 (de) * 2008-04-18 2009-10-21 Merck Sante Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
US20120277238A1 (en) * 2009-07-31 2012-11-01 Shionogi & Co., Ltd Pharmaceutical composition containing fused hetero-ring derivative
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102875549B (zh) * 2012-09-14 2015-11-04 浙江大学 7-芳（甲）胺基-5-胺基-6-氮杂吲哚衍生物及制备与用途
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
HK1046139B (zh) 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
WO2001074813A2 (en) * 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS
CA2460075A1 (en) * 2001-09-12 2003-03-20 Donn Gregory Wishka Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
DE60309852T2 (de) * 2002-03-27 2007-06-06 Glaxo Group Ltd., Greenford Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20080293801A1 (en) * 2003-11-14 2008-11-27 Pfizer Inc. Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
WO2005097129A2 (en) * 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
AU2006207712A1 (en) * 2005-01-19 2006-07-27 F. Hoffmann-La Roche Ag 5-aminoindole derivatives

Also Published As

Publication number Publication date
US7348323B2 (en) 2008-03-25
CN101326187A (zh) 2008-12-17
KR20080068127A (ko) 2008-07-22
US20070142359A1 (en) 2007-06-21
EP1963318B1 (de) 2009-11-25
CA2631694A1 (en) 2007-06-21
WO2007068620A1 (en) 2007-06-21
BRPI0619989A2 (pt) 2011-10-25
JP2009519290A (ja) 2009-05-14
EP1963318A1 (de) 2008-09-03
DE602006010738D1 (de) 2010-01-07
IL191751A0 (en) 2008-12-29
ES2334580T3 (es) 2010-03-12
AU2006326135A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
ATE517882T1 (de) Chinolinderivate
TW200738651A (en) Cyclohexyl sulfonamide derivatives
NO20082096L (no) Azaindol-2-karboksamidderivativer
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
ATE384058T1 (de) Thiazolderivate
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
TW200612936A (en) Indole derivatives
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
EA201100872A1 (ru) Производные хиназолинамида
CY1119248T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
TW200626158A (en) Naphthaline derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
TW200637817A (en) 5-aminoindole derivatives
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE481395T1 (de) Cyclohexylderivate
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1963318

Country of ref document: EP